###begin article-title 0
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 394 399 <span type="species:ncbi:9606">human</span>
Amyotrophic lateral sclerosis (ALS) is a fatal disorder caused by the progressive degeneration of motoneurons in brain and spinal cord. Despite identification of disease-linked mutations, the diversity of processes involved and the ambiguity of their relative importance in ALS pathogenesis still represent a major impediment to disease models as a basis for effective therapies. Moreover, the human motor cortex, although critical to ALS pathology and physiologically altered in most forms of the disease, has not been screened systematically for therapeutic targets.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 140 148 <span type="species:ncbi:9606">patients</span>
By whole-genome expression profiling and stringent significance tests we identify genes and gene groups de-regulated in the motor cortex of patients with sporadic ALS, and interpret the role of individual candidate genes in a framework of differentially expressed pathways. Our findings emphasize the importance of defense responses and cytoskeletal, mitochondrial and proteasomal dysfunction, reflect reduced neuronal maintenance and vesicle trafficking, and implicate impaired ion homeostasis and glycolysis in ALS pathogenesis. Additionally, we compared our dataset with publicly available data for the SALS spinal cord, and show a high correlation of changes linked to the diseased state in the SALS motor cortex. In an analogous comparison with data for the Alzheimer's disease hippocampus we demonstrate a low correlation of global changes and a moderate correlation for changes specifically linked to the SALS diseased state.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
Gene and sample numbers investigated allow pathway- and gene-based analyses by established error-correction methods, drawing a molecular portrait of the ALS motor cortex that faithfully represents many known disease features and uncovers several novel aspects of ALS pathology. Contrary to expectations for a tissue under oxidative stress, nuclear-encoded mitochondrial genes are uniformly down-regulated. Moreover, the down-regulation of mitochondrial and glycolytic genes implies a combined reduction of mitochondrial and cytoplasmic energy supply, with a possible role in the death of ALS motoneurons. Identifying candidate genes exclusively expressed in non-neuronal cells, we also highlight the importance of these cells in disease development in the motor cortex. Notably, some pathways and candidate genes identified by this study are direct or indirect targets of medication already applied to unrelated illnesses and point the way towards the rapid development of effective symptomatic ALS therapies.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 762 763 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 983 984 983 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 985 986 985 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 95 102 <span type="species:ncbi:9606">persons</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disorder affecting 1-2 in 100,000 persons. It is caused by the degeneration of motoneurons in brain and spinal cord, leading to muscle atrophy, progressive paralysis, and death, commonly by respiratory failure. Most cases of ALS are sporadic (SALS) and about 10% familial (FALS), with mutant forms of copper-zinc superoxide dismutase (SOD1) causing 20% of FALS cases. Findings in ALS patients and model systems have implicated numerous genes in ALS pathogenesis, and have identified diverse processes, such as oxidative stress, excitotoxicity, mitochondrial dysfunction, protein aggregation, cytoskeletal abnormalities, impaired axonal transport, inflammation, and apoptosis, as contributing factors [1]. As a mainly sporadic disease affecting multiple cellular processes, ALS therefore suggests itself for comprehensive expression profiling and gene- and pathway-based analyses. The few existing genomics studies of ALS [2-4], however, have had limited genome coverage and have been restricted to gene-based analyses.
###end p 9
###begin p 10
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1171 1172 1171 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1173 1174 1173 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
###xml 656 664 <span type="species:ncbi:9606">patients</span>
###xml 868 876 <span type="species:ncbi:9606">patients</span>
Adding a further layer of complexity, ALS is a highly heterogenous disease, with clinical indicators helping to define ALS subtypes. One such indicator is a differential depletion of motoneurons in motor cortex and spinal cord [5-7], giving significance to the characterization of both tissues. The motor cortex contains upper motoneurons (UMNs), which extend axons traversing the corticospinal tract to signal to the spinal cord, where lower motoneurons (LMNs) relay their signal. The corticospinal tract volume is reduced [8] and UMNs are depleted [9,10] in ALS patients, and UMNs are required for LMN function and muscle control [11]. Most importantly, patients with sporadic, non-SOD1-associated forms of ALS show alterations in the motor cortex, such as increased excitability and reduced inhibitory activity, which are not readily detectable in SOD1-linked FALS patients, thus stressing the particular importance of investigating the motor cortex in SALS subjects [12-14]. Possibly owing to earlier clinical manifestations of defects in LMNs and their easier accessibility to experimenters, however, most investigations of ALS, including previous genomics studies [2-4], focus on the spinal cord and LMNs, leaving ALS-related responses and defects of cellular maintenance in the motor cortex under-investigated.
###end p 10
###begin p 11
###xml 193 201 <span type="species:ncbi:9606">patients</span>
Here we address the importance of UMN abnormalities in SALS pathology and exploit the power of pathway-based significance tests by whole-genome expression profiling of the motor cortex of SALS patients. We identify differentially expressed genes and pathways, interpret the role of candidate genes in ALS pathology using these pathways as a functional outline, and evaluate the implications of our findings for ALS research and the development of ALS therapies.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Expression profiling of the motor cortex of SALS patients
###end title 13
###begin p 14
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 378 386 378 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods </italic>
We investigated the motor cortex of eleven SALS and nine control subjects (see Table 1) with whole-genome oligonucleotide microarrays and following microscopic assessment of tissue architecture (see Figure 1 for Nissl staining of six representative samples). Out of over 41,000 genes and expressed sequence tags tested, 19,431 genes passed our quality control criteria (see the Methods section), constituting our complete data set for subsequent analyses. Median and average fold-changes of our complete data set were 1.01 (Diseased vs. Control), establishing that no systematic bias for up- or down-regulation was introduced into subsequent statistical analyses.
###end p 14
###begin p 15
Characteristics of subjects
###end p 15
###begin p 16
###xml 269 271 265 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 99 104 <span type="species:ncbi:9606">Human</span>
###xml 242 250 <span type="species:ncbi:9606">patients</span>
20 motor-cortex samples of eleven ALS patients and nine controls were analyzed on individual Whole Human Genome Arrays for genome-wide expression profiling. Age, gender, race, and post-mortem interval (mean controls 12.47 +/- 6.06 h and mean patients 16.35 +/- 6.37 h, P = 0.21) are shown for all tissue samples. A - Miami Brain and Tissue Bank for Developmental Disorders; B - Ambion, Inc.; n/a - not available
###end p 16
###begin p 17
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Architecture of the motor cortex in SALS and control samples</bold>
Architecture of the motor cortex in SALS and control samples. Nissl staining of representative SALS samples (D2, D4, D5) and controls (H1, H3, H4) shows the intact architecture of the motor cortex in samples chosen for expression analysis. All samples are shown at identical magnification. Cell layers are color-coded as indicated for sample D2. ML - molecular layer; EGL - external granular layer; EPL - external pyramidal layer; IGL - internal granular layer; IPL - internal pyramidal layer; MFL - multiform layer; WM - white matter. The scale bar indicates 500 mum.
###end p 17
###begin p 18
To exploit the comprehensiveness of our data, we combined two complementary, stringent approaches, investigating changes in the SALS motor cortex for functional gene groups and on the level of individual genes.
###end p 18
###begin title 19
Pathway-based analysis
###end title 19
###begin p 20
###xml 1718 1720 1718 1720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1908 1909 1908 1909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1921 1922 1921 1922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
We first performed a pathway-based analysis of the complete data set by testing changes of gene expression in the context of 5137 gene groups of the gene ontology (GO) hierarchy, using the GenMAPP 2.0 software. Analyses on the level of functional gene groups lead to a biologically transparent picture of expression, accessible to interpretation. What is more, by combining measurements for functionally related genes this approach increases the sensitivity of detecting significant changes when differential gene expression is diluted in a mixed cell population (leading to comparably low fold changes) and with small to moderate sample numbers (possibly leading to a high variance for inconsistently de-regulated genes). In such instances individual genes will not pass statistical criteria for differential gene expression, while moderate deregulation of multiple genes constituting a functional group might test highly significant. Indeed, the statistical significances we derived from GenMAPP 2.0, using the average fold-change per gene as a basis for statistical tests, is independent of the number of samples and highly dependent on the number of genes represented by our data, while the quality filtering and the comparably large number of samples used in this study avoid the detection of spurious results and promote a correspondence between statistical and biological significance. In other words, 5137 GO categories were probed with 19,431 quality filtered genes, and 20 samples were used to derive representative average fold-changes to do so. GenMAPP detected 5033 GO categories as unchanged, while 104 partially redundant categories exhibited significantly changed expression in ALS subjects (corrected P < 0.05). Significant GO categories fell into six major processes of relevance in the context of a comprehensive ALS disease model, five of them down-regulated and one up-regulated (Figure 2; see Table 2 for the full list of significantly changed GO categories).
###end p 20
###begin p 21
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gene Ontology nodes differentially expressed in motor cortex of SALS subjects</bold>
###xml 222 239 222 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">energy metabolism</italic>
###xml 241 277 241 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ion homeostasis and solute transport</italic>
###xml 279 296 279 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">defense signaling</italic>
###xml 298 331 298 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">protein modification and turnover</italic>
###xml 333 345 333 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytoskeleton</italic>
###xml 351 361 351 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glycolysis</italic>
###xml 775 775 775 775 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1471-2164-8-26-i1.gif"/>
###xml 798 798 798 798 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1471-2164-8-26-i2.gif"/>
###xml 891 893 891 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Gene Ontology nodes differentially expressed in motor cortex of SALS subjects. Significant Gene Ontology (GO) nodes were combined to groups likely representing major processes in the context of ALS pathology, specifically energy metabolism, ion homeostasis and solute transport, defense signaling, protein modification and turnover, cytoskeleton, and glycolysis, and are arranged indicating the predominant intracellular localization of the gene products they comprise. The basic categories Biological Process, Cellular Component, and Molecular Function are color-coded. Connecting arrows indicate the order of nodes in the GO hierarchy. For each major process only the highest node(s) of significance (â—‡) and the most significant node (!) are shown per basic category. Up- () and down-regulation (), the absolute number and percentage of genes meeting the criterion, z score, and corrected P value are indicated for each node. Redundant nodes are left out within the same category, or combined if in different categories.
###end p 21
###begin p 22
Differentially regulated GO categories
###end p 22
###begin p 23
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 74 81 <span type="species:ncbi:9606">patient</span>
Shown are all GO nodes differentially regulated between SALS motor-cortex-patient samples and controls for the comprehensive dataset. Of 19,431 probes in the dataset, 8,457 were linked to a GO term. Nodes are sorted by up- or down-regulation (top and bottom sub-tables, respectively), then sorted by corrected P value (lowest first) and z value (highest first). CC - cellular component; MF - molecular function; BP - biological process
###end p 23
###begin title 24
Identification of candidate genes
###end title 24
###begin p 25
###xml 274 282 274 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods </italic>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 561 569 561 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-situ </italic>
We then analyzed the complete data set for individual genes showing differential gene expression, finding that 57 of the 19,431 quality-filtered genes (0.3%) fulfilled our stringent criteria (including Benjamini and Hochberg multiple testing correction, for details see the Methods section), with 40 genes showing down-regulation and 17 up-regulation in SALS subjects (Figure 3). In contrast to results for large gene groups, differential expression of individual mRNAs is readily verifiable by alternative techniques, such as quantitative RT-PCR (qRT-PCR) and in-situ hybridization.
###end p 25
###begin p 26
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genes differentially expressed in motor cortex of SALS subjects</bold>
###xml 175 177 175 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 734 736 734 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Genes differentially expressed in motor cortex of SALS subjects. 57 of 19,431 quality-filtered genes (0.3%), represented by 61 probes, are differentially expressed (corrected P < 0.05), with each row in the matrix representing a single probe and each column a subject. Normalized expression levels are represented by the color of the corresponding cell, relative to the median abundance of each gene for each subject (see scale). Genes are named using their UniGene symbol and arranged in a hierarchical cluster (standard correlation) based on their expression patterns, combined with a dendrogram whose branch lengths reflect the relatedness of expression patterns. For each gene the fold-change (diseased vs. control) and corrected P value are given.
###end p 26
###begin title 27
Confirmation by quantitative RT-PCR
###end title 27
###begin p 28
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1B</italic>
###xml 402 406 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1E</italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1G</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1L</italic>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1M</italic>
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1X</italic>
###xml 432 436 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT2A</italic>
###xml 956 957 956 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1222 1226 1222 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1B</italic>
###xml 1285 1289 1285 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1L</italic>
The 60-mer oligonucleotide format of microarrays used in this study may provide tolerance for sequence mismatches. To investigate probe-target specificity, the sequences of oligonucleotide probes corresponding to differentially expressed genes were compared to GenBank sequences by BLASTN queries. The only probes showing up to ten mismatches with more than one gene were seven metallothioneins (MT1B, MT1E, MT1G, MT1L, MT1M, MT1X, MT2A). To discriminate among these homologous genes and analyze their differential expression we used qRT-PCR. PVALB, down-regulated in the ALS motor cortex, was also included in our qRT-PCR analysis as a positive control for the correspondence of microarray and qRT-PCR data. In contrast to the metallothionein probes the PVALB probe, representative of probes for the remaining candidates, detects transcripts for a single gene, only. PVALB and six of the metallothioneins were specifically quantifiable by qRT-PCR (Figure 4). Microarray and qRT-PCR results were concordant (correlation coefficient r = 0.91, comparing individual test and control averages for the seven genes tested), confirming up-regulation of six metallothioneins and down-regulation of PVALB in the SALS motor cortex. MT1B, whose microarray probe shares 87% sequence identity with MT1L, could not be detected specifically by three independent primer pairs, and was excluded from subsequent analyses.
###end p 28
###begin p 29
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Comparison of microarray and qRT-PCR results for selected candidate genes</bold>
###xml 374 376 374 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Comparison of microarray and qRT-PCR results for selected candidate genes. The bar graph shows mean results of expression levels in SALS vs. control subject. Fold-changes are shown diseased vs. control, and differed by less than 1.2-fold between qRT-PCR and microarray, except for MT1E and MT2A. Error bars for qRT-PCR data indicate the range for duplicate experiments. The P values for qRT-PCR and microarray (most significant probe) data were 0.342 and 0.020 (MT1E), 0.063 and 0.023 (MT1G), 0.037 and 0.025 (MT1L), 0.119 and 0.026 (MT1M), 0.074 and 0.031 (MT1X), 0.063 and 0.011 (MT2A), and 0.037 and 0.011 (PVALB).
###end p 29
###begin title 30
###xml 16 24 16 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-situ </italic>
Confirmation by in-situ hybrization
###end title 30
###begin p 31
###xml 158 166 158 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-situ </italic>
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANXA2</italic>
###xml 412 418 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP1A3</italic>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NRGN</italic>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PVALB</italic>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 208 213 <span type="species:ncbi:9606">human</span>
To verify the microarray results in a direct fashion (i.e. without intervening reverse-transcription and amplification steps), we then performed double-blind in-situ hybridization for four candidate genes in human motor cortex sections from five control and five SALS subjects. Median fluorescence levels of entire tissue sections for diseased and control subjects were measured for four candidate genes (ANXA2, ATP1A3, NRGN, and PVALB, see Figure 5), showing a strong correlation with the microarray data (correlation coefficient r = 0.97, comparing individual test and control averages for the four genes tested).
###end p 31
###begin p 32
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Changes of ANXA2, ATP1A3, NRGN, and PVALB mRNAs in motor cortex of SALS subjects</bold>
###xml 82 90 82 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In-situ </italic>
###xml 391 393 391 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Changes of ANXA2, ATP1A3, NRGN, and PVALB mRNAs in motor cortex of SALS subjects. In-situ hybridization analysis of ANXA2, ATP1A3, NRGN, and PVALB mRNAs was performed in duplicate tissue sections of motor cortex from five control and five SALS subjects. Optical density values were normalized against those obtained in control subjects and subjected to two-tailed Student's t-test (with the P values 3.44e-6 (ANXA2), 7.91e-3 (ATP1A3), 2.29e-5 (NRGN) and 2.88e-6 (PVALB), respectively, diseased vs. control). The bar graph shows mean results and the standard deviation of the mean of labeling in control and SALS subjects.
###end p 32
###begin title 33
Confirmation at the protein level
###end title 33
###begin p 34
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1122 1124 1122 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1244 1246 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
We then proceeded to validate our findings for mRNAs at the level of proteins, which for the overwhelming majority of RNAs investigated in this study represent the biologically active equivalent. While individual genes may show discrepancies between mRNA and protein levels, owing to translational and post-translational control, an on average fair correlation between protein and mRNA levels can be expected in mammalian systems [15]. Protein extracts of three healthy and six diseased samples, equalized for total protein content, were analyzed by immunoblotting (see Figure 6A and 6B). Quantification of protein levels revealed an up-regulation for ANXA2 (18.56-fold) and AQP1 (4.94-fold), and a down-regulation of NRGN (0.38-fold) in diseased samples. These findings were in line with and exceeded the fold-changes of 2.06, 2.52, and 0.49, respectively, detected by microarray-based analysis for the corresponding mRNAs. Remarkably, AQP1 is generally assumed to be absent from the motor cortex, with a predominant expression in the brain in the choroid plexus [16] and in glial cells in the peripheral nervous system [17]. We therefore also performed immunofluorescence analyses of motor-cortical sections to elaborate our findings (Figure 6C), demonstrating the presence of AQP1 in non-neuronal cells in the motor cortex.
###end p 34
###begin p 35
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunodetection of selected candidate genes</bold>
###xml 612 614 612 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Immunodetection of selected candidate genes. (A) Immunoblots for ANXA2, AQP1, NRGN, and CANX was performed for three control and six diseased subjects. The size of quantified bands is indicated in kDa. The glycosylated form of AQP1 (*), undetectable in the healthy samples analyzed, was not included in the analysis. CANX served as a reference gene for sample normalization. (B) Bar graph comparing fold-changes of mean expression levels diseased vs. control as detected by immunoblot and microarray. Normalized intensity values are shown diseased vs. control and were analyzed by a two-tailed Student's t-test. P values for immunoblot and microarray (most significant probe) data were 0.025 and 0.011 (ANXA2), 0.055 and 0.036 (AQP1), and 0.047 and 0.023 (NRGN), respectively). (C) Immunofluorescence detection of AQP1 expression in non-neuronal cells in the diseased (D) and the healthy (H) motor cortex. NF - neurofilaments (red); AQP1 - aquaporin 1 (green); DNA - Hoechst33342 counterstain (blue). The scale bar indicates 100 mum.
###end p 35
###begin title 36
Comparison with SALS spinal-cord and AD hippocampus expression data
###end title 36
###begin p 37
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 402 410 402 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods </italic>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
We then compared expression ratios diseased vs. control for the SALS motor cortex to previously published data for spinal cord grey matter [4]. A comparison of all 2266 genes reliably detected in both tissues showed a negligible correlation (r = 0.04), while 23 of the motor-cortex candidate genes also present in the reduced data set showed a high correlation (r = 0.85) between both tissues (see the Methods section and Table 3).
###end p 37
###begin p 38
Comparison of expression ratios in motor cortex and spinal cord
###end p 38
###begin p 39
###xml 326 334 326 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods </italic>
Expression ratios for candidate genes identified in the present report (Motor Cortex) are compared to those found by Dangond et al. [4] (Spinal Cord), giving a correlation coefficient of r = 0.85. Spinal cord data were retrieved from the Gene Expression Omnibus Database (GEO, series GSE833) and processed as described in the Methods section.
###end p 39
###begin p 40
== both tissues give the same result, differing </=1.5-fold
###end p 40
###begin p 41
= both tissues give the same result, differing >1.5-fold
###end p 41
###begin p 42
<> both tissues give different results (up- vs. down-regulation or deregulation vs. constancy, defining constancy as a </=1.5-fold deregulation)
###end p 42
###begin p 43
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 578 586 578 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods </italic>
###xml 604 605 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
To assess in how far responses detected in the motor cortex of SALS patients might be shared with other neurodegenerative diseases, we then compared our data to expression ratios diseased vs. healthy for previously published data by Blalock et al. [18] for the hippocampus of patients with severe Alzheimer's disease (AD). A comparison of all 6375 genes reliably detected in both tissues showed a low correlation (r = 0.38), while 38 of the motor-cortex candidate genes also present in the reduced data set showed a moderate correlation (r = 0.70) between both tissues (see the Methods section and Table 4).
###end p 43
###begin p 44
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Comparison of expression ratios in patients with SALS and Alzheimer's disease
###end p 44
###begin p 45
###xml 298 306 298 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods </italic>
Expression ratios for candidate genes identified in the present report (SALS) are compared to those found for data by Blalock et al. [18] for Alzheimer's disease (AD), giving a correlation coefficient of r = 0.696. AD data were retrieved from GEO (series GSE1297) and processed as described in the Methods section.
###end p 45
###begin p 46
== both tissues give the same result, differing </=1.5-fold
###end p 46
###begin p 47
= both tissues give the same result, differing >1.5-fold
###end p 47
###begin p 48
<> both tissues give different results (up- vs. down-regulation or deregulation vs. constancy, defining constancy as a </=1.5-fold deregulation)
###end p 48
###begin p 49
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 686 703 686 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP biosynthesis </italic>
###xml 707 718 707 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glycolysis </italic>
###xml 821 838 821 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">defense response </italic>
###xml 842 867 842 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">microtubule-based process</italic>
###xml 1127 1133 1127 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP1A3</italic>
###xml 1135 1139 1135 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGR1</italic>
###xml 1145 1150 1145 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHGB </italic>
###xml 1245 1250 1245 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANXA2</italic>
###xml 1252 1259 1252 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP6V1A</italic>
###xml 1261 1267 1261 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EIF4A2</italic>
###xml 1269 1272 1269 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NSF</italic>
###xml 1332 1336 1332 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1E</italic>
###xml 1338 1342 1338 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1G</italic>
###xml 1344 1348 1344 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1X</italic>
###xml 1350 1354 1350 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT2A</italic>
Despite the distinctive clinical manifestations of AD and its action on different areas of the central nervous system, therefore, global responses in the AD hippocampus correspond more closely to those in the SALS motor cortex than do those in the SALS spinal cord. This observation might reflect similar general changes in both brain tissues under long-term stress and after prolonged disease pathology, and ties in with the implication of processes such as oxidative stress, reduced energy metabolism, intracellular protein aggregation, and inflammation in both, AD and ALS pathogenesis. Importantly and similar to our findings for the SALS motor cortex, Blalock et al. [18] detected ATP biosynthesis and glycolysis by pathway-based analysis as significantly reduced in AD, and found deregulation in line with ours for defense response and microtubule-based process, albeit below the significance threshold. Changes significantly linked to the diseased state in our study, however, are highly correlated between SALS motor cortex and spinal cord, and less similar between SALS motor cortex and AD hippocampus. In particular, ATP1A3, EGR1, and CHGB experience opposing deregulation in the SALS motor cortex compared to the AD hippocampus, with ANXA2, ATP6V1A, EIF4A2, NSF, and all the metallothioneins detected in the hippocampus (MT1E, MT1G, MT1X, MT2A) also showing markedly different regulation between both tissues.
###end p 49
###begin title 50
Discussion
###end title 50
###begin title 51
A framework for the understanding of ALS pathogenesis
###end title 51
###begin p 52
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
A combination of candidate genes and pathway-based analysis provided a comprehensive view, at the level of mRNA, of the processes involved in ALS pathogenesis, suggesting an interpretation of changes in gene expression within a framework of deregulated pathways (Figure 7). It should be pointed out that, inherent to the analysis of end-stage diseased tissue, microarray analysis cannot distinguish between bona-fide up- and down-regulation of a gene and the selective survival and death, respectively, of cells highly expressing it. This ambiguity generally does not alter the interpretation of the role a given candidate gene with an established function might play in disease pathology. Moreover, selective cell death or survival appear unlikely explanations for the identification of candidate genes with two-fold changes of expression. However, this limitation needs to be borne in mind and will not be re-itterated in the course of the discussion. Nearly all candidate genes identified by this study may be actors in ALS pathogenesis based on their existing characterizations, and some of them stand out as potentially critical to de-regulated processes and to ALS therapy.
###end p 52
###begin p 53
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The interplay of cell types and pathways in SALS pathology</bold>
###xml 418 418 418 418 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1471-2164-8-26-i1.gif"/>
###xml 440 440 440 440 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1471-2164-8-26-i2.gif"/>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EIF4A2</italic>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GNAS</italic>
###xml 480 487 480 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAP1L5 </italic>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
The interplay of cell types and pathways in SALS pathology. Combining pathways and candidate genes differentially expressed in the motor cortex of SALS patients reveals a complex interplay of cellular processes and cell types. Candidate genes corresponding to major pathways discussed in the main text are color-coded, placed in the cell type(s) where they most likely exert their influence, and their individual up- () or down-regulation () is indicated. Genes EIF4A2, GNAS, and NAP1L5 are left out for clarity.
###end p 53
###begin title 54
Mitochondrial energy metabolism
###end title 54
###begin p 55
###xml 0 32 0 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mitochondrial energy metabolism </italic>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDH1</italic>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYCS</italic>
###xml 247 254 247 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NDUFA4 </italic>
###xml 258 264 258 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP5A1</italic>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1282 1284 1282 1284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1337 1339 1337 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1493 1494 1493 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1608 1610 1608 1610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1834 1835 1834 1835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1890 1892 1890 1892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2306 2308 2306 2308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 2373 2381 <span type="species:ncbi:9606">patients</span>
Mitochondrial energy metabolism is a process down-regulated at the mRNA level and represented by all three major GO categories and by genes contributing to the tricarboxylic acid (TCA) cycle (MDH1) and involved in oxidative phosphorylation (CYCS, NDUFA4 and ATP5A1). The TCA accepts glycolysis-derived pyruvate as a key entry component. An alternative route for the supply of the TCA with pyruvate is its import downstream of the down-regulated MDH1, the cytosolic malate dehydrogenase [19]. Downstream of the TCA, oxidative phosphorylation occurs, for which we detected a specific down-regulation of genes encoding NDUFA4, a component of complex I of the electron transport chain in the inner mitochondrial membrane, CYCS, facilitating electron transport from complex III to complex IV in the intramembrane space, and ATP5A1, a component of the ATP synthase in the inner mitochondrial membrane. Importantly, the down-regulated CYCS is not only a component of mitochondrial oxidative phosphorylation, but also represents a cytoplasmic signal for neuronal apoptosis as a result of impaired mitochondrial integrity. Opening of the mitochondrial transition pore normally serves the ion exchange between matrix and cytosol, but is thought to be exaggerated upon excitotoxic levels of Ca2+, leading to release of CYCS from the mitochondrion [20]. CYCS release, its activation of cellular caspases, and subsequent apoptosis have been proposed as a contributing factor to neuronal cell death in ALS [1]. A lowered expression of CYCS, however, would conceivably decrease the sensitivity to stress-induced apoptosis [21]. More significantly, our observations expand a role for mitochondrial dysfunction in the death of ALS motoneurons, which is otherwise mainly understood as a consequence of mitochondrial recruitment of mutant SOD1 in FALS [1], and which was even ruled out for SALS by one study [22]. Importantly, the significant down-regulation of GO nodes relating to mitochondria can not be the mere consequence of mitochondrial dysfunction or reduced numbers of mitochondria, as the GO hierarchy does not represent mitochondrion-encoded transcripts. Moreover, nuclear-encoded transcripts encoding mitochondrial proteins are universally induced during conditions of oxidative stress and mitochondrial damage [23], contrary to our observations for motor-cortical cells of SALS patients.
###end p 55
###begin title 56
Glycolysis
###end title 56
###begin p 57
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glycolysis </italic>
###xml 447 454 447 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 482 486 482 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHGB</italic>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCG5</italic>
###xml 494 499 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCSK1</italic>
###xml 523 531 523 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4 </italic>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Glycolysis was detected as significantly down-regulated in the SALS motor cortex by pathway-based analysis of our microarray data. Glycolysis represents the cytoplasmic alternative to mitochondrial ATP generation by the TCA cycle and by oxidative phosphorylation, but is also a major source of pyruvate supply to the TCA cycle. At the level of individual genes, significant changes in gene expression similarly indicate a reduction of glycolysis (ANGPTL4) and glucose availability (CHGB, SCG5, PCSK1). The up-regulation of ANGPTL4 reduces expression of genes involved in glycolysis and gluconeogenesis [24]. The down-regulation of granins CHGB and SCG5, both processed by the down-regulated prohormone convertase PCSK1, increases insulin levels, hence reducing the availability of glucose for glycolysis [25]. In the context of ALS-related oxidative stress and neuronal modulation of ion gradients, a reduction of glycolytic energy supply, in combination with reduced mitochondrial energy supply, would constitute a major cause for neuronal cell death.
###end p 57
###begin title 58
Ion homeostasis and solute transport
###end title 58
###begin p 59
###xml 0 37 0 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ion homeostasis and solute transport </italic>
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 195 244 195 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">monovalent inorganic cation transporter activity </italic>
###xml 289 322 289 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hydrogen ion transporter activity</italic>
###xml 336 338 336 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 479 510 479 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sodium ion transporter activity</italic>
###xml 524 526 524 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 558 588 558 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">metal ion transporter activity</italic>
###xml 601 603 601 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 660 697 660 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ion homeostasis and solute transport </italic>
###xml 751 765 751 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">excitotoxicity</italic>
###xml 767 786 767 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">calcium homeostasis</italic>
###xml 792 818 792 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">water and solute transport</italic>
Ion homeostasis and solute transport is detected as reduced at the mRNA level by pathway-based analysis and covers both cytoplasmic and mitochondrial events (see Table 2). For instance, 71.7% of monovalent inorganic cation transporter activity includes genes involved in proton transport (hydrogen ion transporter activity, z = 13.444, P = 0), commonly associated with organelle membranes (e.g. of mitochondria and lysosomes), and genes involved in the transport of sodium ions (sodium ion transporter activity, z = 10.059, P = 0) and metal ions in general (metal ion transporter activity, z = 8.147, P = 0), more commonly associated with the plasma membrane. Ion homeostasis and solute transport comprises three groups of candidate genes relating to excitotoxicity, calcium homeostasis, and water and solute transport, respectively.
###end p 59
###begin p 60
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Excitotoxicity</italic>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 531 537 531 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP1A3</italic>
###xml 539 544 539 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KCNC2</italic>
###xml 550 557 550 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC12A5</italic>
###xml 594 595 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 597 599 597 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 877 884 877 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP1A3 </italic>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1306 1308 1306 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1311 1319 1311 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC12A5 </italic>
###xml 1446 1454 1446 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC12A5 </italic>
###xml 1775 1783 1775 1783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC12A5 </italic>
###xml 1856 1864 1856 1864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-vivo </italic>
###xml 1879 1881 1879 1881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1894 1902 1894 1902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC12A5 </italic>
###xml 1988 1990 1988 1990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 334 339 <span type="species:ncbi:9606">human</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 1888 1893 <span type="species:ncbi:10090">mouse</span>
Excitotoxicity, the excessive signaling of glutamate receptors, is a key pathogenic mechanism proposed in ALS, and is aggravated by a weakening of inhibitory synaptic events mediated by the GABAA receptor. Alterations of its composition, such as the depletion of its GABRA1 subunit found in this study, was previously demonstrated in human motor cortex of ALS patients and is associated with heightened excitability [26]. Increased excitability, and hence exacerbated excitotoxicity, may also derive from the reduced expression of ATP1A3, KCNC2, and SLC12A5. Mutations of the plasma-membrane Na+/K+ pump ATP1A3 have been linked to rapid-onset dystonia-parkinsonism [27]. Moreover, ATP1A3 expression is reduced in SOD1(G93A) FALS mice [28] and in motoneurons of Wobbler mice, a genetic model of spinal-cord motoneuronal degeneration, with progesterone treatment restoring both, ATP1A3 mRNA expression and viability of motoneurons [29]. KCNC2 regulates the voltage-dependent potassium ion permeability of excitable membranes, and its decreased expression may lead to decreased potassium conductance and hence delayed repolarization of axons. While KCNC2 itself is poorly characterized, defects in other voltage-gated potassium channels can lead to hyperexcitability and hypersensitivity to oxidative stress [30]. SLC12A5 encodes the neuronal isoform of the potassium-chloride cotransporter family. During early development, increased expression of SLC12A5 lowers the intraneuronal chloride concentration below its electrochemical equilibrium and allows GABA to act as an inhibitory neurotransmitter. Conversely, a switch of GABA action from inhibitory to excitatory has been proposed as a mechanism contributing to excitotoxicity in injured neurons. Indeed, down-regulation of SLC12A5 expression together with GABAA receptor-mediated excitation occurs after in-vivo axonal injury [31], and mouse SLC12A5 knockouts suffer severe motor deficits and immediate postnatal death by asphyxiation [32].
###end p 60
###begin p 61
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Calcium homeostasis </italic>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PVALB</italic>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DSCR1L1</italic>
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NRGN</italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCP4 </italic>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
Calcium homeostasis and calcium-binding proteins are critical to preventing motoneuron death in ALS, and with PVALB, DSCR1L1, NRGN, and PCP4 we found four genes down-regulated in the ALS motor cortex that moderate the impact of intracellular calcium release. There is disagreement whether the calcium buffer PVALB represents a marker of motoneurons resistant to ALS-related cell death [33,34], but its reduction would likely increase cell death at the elevated calcium concentration typical of ALS [35]. Similarly, DSCR1L1 is an inhibitor of calcineurin [36], a mediator of many cellular responses, including apoptosis [37]. Depletion of the two calmodulin-binding proteins NRGN and PCP4, involved in moderating calmodulin-mediated calcium signaling, would further reduce resistance to calcium-mediated toxicity [38,39].
###end p 61
###begin p 62
###xml 0 27 0 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Water and solute transport </italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AQP1 </italic>
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC14A1</italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AQP1 </italic>
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC14A1</italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
Water and solute transport is represented by the up-regulation of AQP1 and SLC14A1. Both, AQP1 and SLC14A1, experience up-regulation with age and by hypertonicity [40], and like AQP1 the urea transporter SLC14A1 may also function as an efficient water transporter [41]. Their joint up-regulation found in this study is indicative of disturbed ion and water homeostasis in the motor cortex of SALS patients. The water transporter AQP1 in particular is of interest through its association with synaptic vesicles and participation in their swelling in cells outside the central nervous system [42].
###end p 62
###begin title 63
Protein modification and turnover
###end title 63
###begin p 64
###xml 0 34 0 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Protein modification and turnover </italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 556 557 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1127 1129 1127 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1300 1306 1300 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCHL1 </italic>
###xml 1464 1466 1464 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1639 1641 1639 1641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1699 1701 1699 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1786 1788 1786 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 995 1001 <span type="species:ncbi:10090">murine</span>
###xml 1339 1347 <span type="species:ncbi:9606">patients</span>
Protein modification and turnover are essential to motoneuron survival, resulting in the selective death of motoneurons upon chemical inhibition of the proteasome complex [43], which we detected as down-regulated in SALS samples by pathway-based analysis of our microarray data, thus stressing a role of disturbed protein turnover in ALS pathogenesis. Indeed, the progressive accumulation of polyubiquitinated protein conjugates, indicating a failure of proteasomal turnover, is a consistent feature of many neurodegenerative diseases [44], including ALS [1]. In line with this we also observed the down-regulation of UCHL1, a neuron-specific ubiquitin carboxy-terminal hydrolase-1, which also displays a secondary dimerization-dependent ubiquitin-ligase activity and represents up to 2% of total soluble brain protein [45]. A point mutation affecting the ligase activity of UCHL1 has been linked to Parkinson's disease [46], while an internal 42-amino-acid deletion in UCHL1 is responsible for murine gracile axonal dystrophy, which is characterized by axonal degeneration and formation of spheroid bodies in nerve terminals [47]. The latter phenotype and the observation of poly-ubiquitinated aggregates in ALS create a tantalizing link between the hydrolase activity of UCHL1 and the depletion of UCHL1 mRNA in the motor cortex of SALS patients. Up-regulation of SERPINA3, a serine protease inhibitor enriched in neurofilament conglomerates of ALS motoneurons [48], can be seen in the same light and has been associated with other neurodegenerative diseases. In Alzheimer's disease, for instance, its astrocytic expression is elevated [49] and exacerbates the accumulation of protein aggregates [50]. SERPINA3 also has other effects, however, including protection against microglia [51].
###end p 64
###begin title 65
Cytoskeleton
###end title 65
###begin p 66
###xml 4 17 4 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytoskeleton </italic>
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB2A</italic>
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB6</italic>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 787 791 787 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1053 1055 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1068 1070 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1200 1201 1200 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1535 1538 1535 1538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF </italic>
###xml 1609 1612 1609 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF </italic>
###xml 1646 1648 1646 1648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1725 1727 1725 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1779 1783 1779 1783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 1932 1937 1932 1937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1 </italic>
###xml 1963 1965 1963 1965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 2022 2023 2022 2023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 2024 2026 2024 2026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 2027 2029 2027 2029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 804 808 <span type="species:ncbi:10090">mice</span>
###xml 891 896 <span type="species:ncbi:9606">human</span>
###xml 1041 1051 <span type="species:ncbi:7227">Drosophila</span>
###xml 1061 1066 <span type="species:ncbi:10090">mouse</span>
###xml 1800 1804 <span type="species:ncbi:10090">mice</span>
The cytoskeleton is critical for neuronal maintenance and plasticity, neurite outgrowth, axonal caliber and transport. Our analysis reveals the alteration of two major components of the neuronal cytoskeleton in the ALS motor cortex at the mRNA level, showing a general down-regulation of microtubules by pathway-based analysis and deregulation of two genes encoding tubulin beta (TUBB2A, TUBB6), as well as decreased expression of all three neurofilament subunits (NEFL, NEF3, NEFH). A depletion of microtubules and neurofilaments has deleterious effects on motoneurons, according to our present understanding of their role in ALS pathogenesis [1]. Impaired microtubule-based axonal transport causes related motoneuropathies and is the earliest detectable, presymptomatic abnormality in SOD1-mutant FALS mice. What is more, defects in microtubule-associated motor proteins cause ALS-related human motoneuropathies, such as Charcot-Marie-Tooth disease 2A [52] and hereditary spastic paraplegia [53], and are responsible for ALS phenotypes in Drosophila [54] and mouse [55]. The role of neurofilaments (NFs) in ALS is still controversial, despite a substantial body of research addressing the subject [1]. NF assemblies have been suggested as a possible impediment to axonal transport, either as its aberrantly crosslinked cargoes or in stationary aggregates, and even disturbing the stoichiometric balance between NF subunits can lead to ALS-like morphology and death of motoneurons. However, despite a raised incidence of mutations in NF genes in ALS subjects, a comprehensive study has excluded mutations in NF genes as a primary cause for ALS [56]. Moreover, ALS pathogenesis also progresses without axonal neurofilaments [57], and over-expression of NEFH prolongs survival of SOD1-transgenic FALS mice, prompting the hypothesis that NFs primarily act as an abundant buffer for otherwise deleterious processes, such as actions of SOD1 gain-of-function mutants [58] or aberrant tyrosine nitrosylation or phosphorylation [1,59,60]. The down-regulation of all three NF subunits observed in this study would be detrimental according to either interpretation of NF involvement in ALS pathology, first by interfering with their stoichiometric balance and second by depleting their availability as a potential buffer for aberrant enzymatic activities.
###end p 66
###begin title 67
Neuronal maintenance and signaling
###end title 67
###begin p 68
###xml 11 45 11 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neuronal maintenance and signaling</italic>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAP2</italic>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENC1</italic>
###xml 358 364 358 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLLT11</italic>
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OLFM1</italic>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VSNL1</italic>
###xml 512 516 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX1</italic>
###xml 518 522 518 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHN1</italic>
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RTN1</italic>
###xml 530 534 530 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RTN4</italic>
###xml 536 540 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTN</italic>
###xml 611 618 611 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP6V1A</italic>
###xml 620 623 620 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NSF</italic>
###xml 625 631 625 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNAP25</italic>
###xml 633 638 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SYT13</italic>
###xml 755 756 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 853 857 853 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHN1</italic>
###xml 859 863 859 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTN</italic>
###xml 865 871 865 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNAP25</italic>
###xml 873 878 873 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OLFM1</italic>
###xml 880 885 880 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VSNL1</italic>
###xml 1038 1039 1038 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 946 953 <span type="species:ncbi:9606">patient</span>
Changes in Neuronal maintenance and signaling, detected by gene-based analysis of our microarray data, comprise only down-regulated genes and tie in with observations for disturbed signaling in the motor cortex of sporadic, non-SOD1-linked ALS [12,13]. Depleted are general promoters of neurodifferentiation and axonal and dendritic maintenance (CAP2, ENC1, MLLT11, OLFM1, VSNL1), with clear implications for neuronal survival, but also several inhibitors of differentiation and promoters of cell proliferation (BEX1, CHN1, RTN1, RTN4, NPTN), whose role in ALS pathogenesis is ambiguous. Four additional genes (ATP6V1A, NSF, SNAP25, SYT13) encode proteins regulating synaptic vesicle processing and exocytosis, processes highly relevant to ALS pathology [1]. While most of the above genes are known to be expressed in multiple cell types, some of them (CHN1, NPTN, SNAP25, OLFM1, VSNL1) are neuron-specific. Importantly, we had ensured selecting patient material that exhibited good histological integrity of the motor cortex (see Figure 1), thus minimizing the possibility that observations for neuron-specific genes would reflect the loss of motoneurons typical of ALS.
###end p 68
###begin p 69
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLLT11 </italic>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 345 353 345 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus </italic>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 717 722 717 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAP2 </italic>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 345 352 <span type="species:ncbi:8355">Xenopus</span>
MLLT11 expression is up-regulated in differentiated cortical neurons, and its ectopic expression in embryonic kidney cells triggers the expression of neuronal markers [61]. OLFM1, a secreted glycoprotein, is also strongly expressed in cerebral cortex [62,63] and has been implicated in neural crest development in birds [64] and neurogenesis in Xenopus [65]. ENC1 is a matrix protein expressed almost exclusively in the brain, whose overexpression induces neuronal process formation and whose knock-down inhibits neurite development [66]. Similarly, the calcium-dependent action of VSNL1 has been linked to the promotion of axonal differentiation and to axonal plasticity [67]. The multifunctional protein encoded by CAP2 links the actin cytoskeleton and cAMP signaling, and might therefore facilitate intracellular signal transduction events, dendritic plasticity and synaptic membrane recycling [68,69].
###end p 69
###begin p 70
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 440 445 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTN </italic>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 593 598 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHN1 </italic>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
Amongst the down-regulated inhibitors of neurodifferentiation in the SALS motor cortex are BEX1, a promoter of cell proliferation [70], and RTN1 and RTN4, two members of the reticulon family thought to play an important role in the regulation of neuronal regeneration. RTN4, in particular, is a potent neurite outgrowth inhibitor and has been shown to inhibit the regeneration of severed axons in the mammalian central nervous system [71]. NPTN encodes a protein involved in cell-cell interactions that inhibits neurite outgrowth from dorsal root ganglion and forebrain neurons [72]. Finally, CHN1 encodes the Rac GTPase activating protein alpha-1-chimerin, which mediates the pruning of dendrites in response to synaptic activity [73].
###end p 70
###begin p 71
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 839 841 839 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 1118 1120 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
ATP6V1A is a subunit of the vacuolar proton pump V-ATPase, which generates a proton gradient across the membrane of maturing synaptic vesicles, required for the accumulation of neurotransmitters within them [74]. SNAP25 is a mediator of axonal repair, a regulator of calcium signaling, and a component of the NSF-binding SNARE complex, essential to vesicle fusion and recycling [75], and therefore has an impact on at least three processes critical to ALS pathogenesis. Like alsin, a likely regulator of endosome dynamics and a causative gene for juvenile forms of ALS [1], SNAP25 is also involved in endosome recycling [76], creating a fourth, albeit tentative, link of SNAP25 to ALS pathogenesis. SYT13, like SNAP25, participates in neurite outgrowth and axonal repair, and unlike usual synaptotagmins binds to cellular membranes in a Ca2+-independent fashion to facilitate membrane fusion and exocytosis [77]. It is unclear whether SYT13, like other synaptotagmins, does so by interaction with SNAP25. Following membrane fusions the down-regulated NSF, a key component of internal and exocytotic vesicle transport [78], facilitates the ATP-dependent recycling of SNARE proteins, such as SNAP25.
###end p 71
###begin title 72
Defense signaling
###end title 72
###begin p 73
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Defense signaling </italic>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 862 867 862 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGBP</italic>
###xml 869 874 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YWHAH</italic>
###xml 876 881 876 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANXA2</italic>
###xml 883 889 883 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A8</italic>
###xml 891 895 891 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1</italic>
###xml 897 902 897 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CEBPD</italic>
###xml 919 923 919 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGR1</italic>
###xml 1000 1005 1000 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PNMA2</italic>
###xml 1237 1239 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 1240 1242 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 1486 1491 1486 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGBP</italic>
###xml 1584 1586 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 1660 1662 1660 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 1814 1819 1814 1819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CEBPD</italic>
###xml 2037 2039 2037 2039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 2076 2081 2076 2081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YWHAH</italic>
###xml 2187 2189 2187 2189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 2324 2330 2324 2330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANXA2 </italic>
###xml 2334 2341 2334 2341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100A8 </italic>
###xml 2354 2356 2354 2356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2495 2497 2495 2497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
###xml 2498 2500 2498 2500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B93">93</xref>
###xml 2561 2563 2561 2563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B94">94</xref>
###xml 2625 2627 2625 2627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B95">95</xref>
###xml 2797 2799 2797 2799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B96">96</xref>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
###xml 1139 1146 <span type="species:ncbi:9606">patient</span>
###xml 1624 1632 <span type="species:ncbi:9606">patients</span>
###xml 1954 1962 <span type="species:ncbi:9606">patients</span>
Defense signaling has been implicated in ALS pathogenesis by numerous studies showing inflammatory and immune responses [1], and linking the detection of IgG in ALS motoneurons to neuronal apoptosis [79]. Additional evidence is provided by the detection of IgG in motoneurons of the spinal cord and in pyramidal cells within the motor cortex of ALS patients [80-82] and by the ability of IgG from patients with ALS to induce apoptotic neuronal cell death [79,83,84]. Importantly, IgG purified from ALS patients was found to induce synaptic transmission through interaction with presynaptic membranes, relating autoantibodies in ALS to excitotoxicity [85]. In the present study defense signaling comprises the only up-regulated GO categories in the SALS motor cortex, and is represented by numerous candidate genes, whose differential expression likely promotes (FCGBP, YWHAH, ANXA2, S100A8, EDN1, CEBPD) or suppresses (EGR1, metallothioneins) inflammatory responses, respectively. Down-regulation of PNMA2, whose product is a target of neurodegenerative autoimmune responses, is reminiscent of a PNMA2-autoantibody-associated encephalitis patient with ALS symptoms, who presented with inflammation in cortex and spinal-cord grey matter [86,87]. With a suspected contribution of inflammatory responses to ALS pathogenesis, this suggests the targeting of PNMA2 by neurodegenerative autoimmune responses, leading to a depletion of PNMA2-positive cells. In line with this, the up-regulated FCGBP, encoding an IgG-Fc binding protein, may be involved in immune protection and inflammation [88], and shows elevated serum levels in patients with autoimmune disorders [89]. Elevated levels of FCGBP could therefore contribute to ALS pathogenesis by facilitating autoimmune and neuroinflammatory responses. Up-regulation of CEBPD, encoding a transcription factor of cytokines and other pro-inflammatory response genes, elevated in the brain of Alzheimer's disease patients and itself induced by inflammatory stimuli, ties in with this assumption [90]. Similarly, the down-regulation of YWHAH, a gene linked to schizophrenia that encodes a transcriptional activator of the glucocorticoid receptor [91] and therefore of anti-inflammatory responses, can also be predicted to aggravate neuroinflammation. The up-regulated candidate genes ANXA2 and S100A8 encode two Ca2+-modulated proteins expressed in microglia and are implicated in the intracellular and extracellular regulation of inflammatory responses [92,93]. ANXA2 promotes generation of plasmin on the cell surface [94], a process linked to excitotoxin-induced neurodegeneration [95]. S100A8 mediates inflammatory responses, such as the induction of chemokines, and has been linked to the reduction of cell junction proteins and of membrane integrity [96].
###end p 73
###begin p 74
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1</italic>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B97">97</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B98">98</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B99">99</xref>
###xml 442 446 442 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1</italic>
###xml 496 499 496 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B100">100</xref>
###xml 591 594 591 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B101">101</xref>
###xml 724 727 724 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B101">101</xref>
###xml 728 731 728 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B102">102</xref>
###xml 932 935 932 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B103">103</xref>
###xml 1096 1107 1096 1107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Glycolysis </bold>
###xml 1173 1174 1173 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1175 1178 1175 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B104">104</xref>
###xml 1297 1300 1297 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B103">103</xref>
###xml 1301 1304 1301 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B105">105</xref>
###xml 1362 1366 1362 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGR1</italic>
###xml 1368 1375 1368 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1381 1386 1381 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1 </italic>
###xml 1514 1517 1514 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B106">106</xref>
###xml 1571 1574 1571 1574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B107">107</xref>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 1509 1512 <span type="species:ncbi:9606">man</span>
###xml 1564 1569 <span type="species:ncbi:10090">mouse</span>
The multifunctionality of EDN1 and EGR1 make the consequences of their differential expression in the SALS motor cortex ambiguous. For instance, the up-regulated EDN1, encoding a pro-inflammatory vasoconstrictor peptide, exerts a variety of ALS-aggravating effects, including axonal degeneration [97], impairment of water homeostasis, heightened sensitivity to hypoxic stress [98], and increased excitotoxicity [99]. However, neuron-specific EDN1-knockout mice show elevated sensitivity to pain [100], and EDN1 expression in astrocytes is required for their survival under oxidative stress [101]. Moreover, the hypoxia-inducible EDN1 promotes angiogenesis, reducing the possible effects of hypoxia-related oxidative stress [101,102], amongst other mechanisms by activation of the vascular endothelial growth factor. On the other hand, down-regulation of EGR1, a master switch of inflammatory responses prompted by oxidative stress [103], counteracts angiogenesis, thus increasing hypoxic conditions, but has an anti-inflammatory effect. It is important to note that the up-regulated ANGPTL4 (see Glycolysis above) and the down-regulated EGR1, two inducers of angiogenesis [6,104], represent a positive and a negative target of the hypoxia-induced peroxisome-proliferator-activated receptor gamma [103,105], respectively. Therefore the differential expression of EGR1, ANGPTL4, and EDN1 indicates hypoxic conditions in the SALS motor cortex, tying in with a predisposition for ALS by mutation of angiogenin in man [106] and of vascular endothelial growth factor in mouse [107].
###end p 74
###begin p 75
###xml 279 282 279 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B108">108</xref>
###xml 309 313 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1 </italic>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT2 </italic>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1 </italic>
###xml 535 539 535 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1 </italic>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT2 </italic>
###xml 657 661 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1 </italic>
###xml 677 680 677 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B109">109</xref>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
Indicating protective responses in the SALS motor cortex, we observed the up-regulation at the mRNA level of metallothioneins (MT1E, MT1G, MT1L, MT1M, MT1X, MT2A), neuroprotective, anti-oxidant stress-response proteins induced by metal ions, cytokines, and other stress stimuli [108]. Metallothioneins of the MT1 and MT2 families are expressed in astrocytes, and are increased in spinal cord of ALS patients and in transgenic mutant-SOD1 mice, where their experimental reduction significantly reduces survival. Importantly, endogenous MT1 and MT2 are undetectable in pure motoneuron cultures, which can be protected against oxidative stress by experimental MT1 overexpression [109], indicating the importance of metallothionein-mediated protection normally provided by astrocytes.
###end p 75
###begin title 76
Orphan genes
###end title 76
###begin p 77
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Orphan genes</italic>
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EIF4A2</italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAP1L5</italic>
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GNAS</italic>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 448 451 448 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B110">110</xref>
###xml 469 476 469 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EIF4A2 </italic>
###xml 573 576 573 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B111">111</xref>
###xml 613 617 613 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHGB</italic>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCG5</italic>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCSK1</italic>
###xml 728 739 728 739 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Glycolysis </bold>
###xml 766 773 766 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAP1L5 </italic>
###xml 850 853 850 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B112">112</xref>
###xml 1024 1027 1024 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B113">113</xref>
###xml 1034 1039 1034 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GNAS </italic>
###xml 1077 1083 1077 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAP1L5</italic>
###xml 1099 1102 1099 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B114">114</xref>
###xml 1133 1138 1133 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GNAS </italic>
###xml 1283 1288 1283 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GNAS </italic>
###xml 1372 1383 1372 1383 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Glycolysis </bold>
###xml 523 526 <span type="species:ncbi:10116">rat</span>
###xml 1186 1191 <span type="species:ncbi:9606">human</span>
###xml 1277 1282 <span type="species:ncbi:10090">mouse</span>
Orphan genes, candidate genes with wide-ranging functions (EIF4A2) or without sufficient functional characterization (NAP1L5, GNAS), can only be associated tentatively with major deregulated pathways identified in this study, and were omitted from Figure 7. The down-regulated translation initiation factor EIF4A2 is interchangeable with EIF4A1 for the initiation of translation in general, and induces neural folding during embryonic development [110]. Interestingly, EIF4A2 has also been linked to type-2 diabetes and in rat cells appears to suppress insulin expression [111]. Its down-regulation, like that of CHGB, SCG5, and PCSK1, would therefore lead to elevated insulin levels and hence reduced glucose availability (see Glycolysis above). The down-regulated NAP1L5 is an imprinted and largely uncharacterized gene, highly expressed in brain [112]. NAP1L5 has sequence similarity to NAP1, a cytoplasmic-nuclear shuttle protein for histones, that has large-scale effects on gene expression by chromatin restructuring [113]. The GNAS gene is also down-regulated and, like NAP1L5, is imprinted [114]. Alternative first exons for GNAS transcripts lead to distinct products, which in human have been linked to osteodystrophy and pseudohypoparathyroidism phenotypes, while in mouse GNAS heterozygous mutants show metabolic abnormalities and insulin hypersensitivity (see Glycolysis above).
###end p 77
###begin title 78
Conclusion
###end title 78
###begin title 79
Global reduction of energy supply
###end title 79
###begin p 80
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
Pathway-based and gene-based analyses show a general down-regulation of nuclear genes encoding mitochondrial components in the motor cortex of ALS patients. Although at first glance tying in with ALS-related mitochondrial dysfunction, this observation is at odds with the heightened level of oxidative stress typical of ALS. Numerous studies have characterized oxidative stress as a general inducer of nuclear genes that boost replication, maintenance and repair of mitochondria, as compensatory action for stress-related mitochondrial damage and death (see [23]). The down-regulation observed in the present study suggests alternative signaling to achieve a targeted depletion of mitochondrial components in the SALS motor cortex, which might therefore be a cause rather than a consequence of ALS pathology.
###end p 80
###begin p 81
###xml 328 331 328 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B115">115</xref>
###xml 443 446 443 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B116">116</xref>
As for mitochondrial energy supply, pathway-based and gene-based analyses have independently indicated a reduction in glycolytic activity. Experimental inhibition of glycolysis in an FALS cell-culture model diminishes cell viability, suggesting that ALS-related mitochondrial dysfunction critically reduces cellular ATP supply [115], while hypoglycemia is a strong inducer of oxidative stress, even in the absence of such aggravating factors [116]. Now our results indicate that reduction in glycolytic energy supply is in itself a factor contributing to ALS pathology, suggesting as one overriding cause of ALS-related neuronal cell death the depletion of intracellular ATP levels by a combined reduction of the TCA cycle, oxidative phosphorylation and glycolysis.
###end p 81
###begin p 82
###xml 96 99 96 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B117">117</xref>
###xml 118 121 118 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B118">118</xref>
###xml 226 229 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 364 367 364 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 473 475 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 609 611 609 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 615 617 615 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Reduced intracellular ATP levels lead to increased susceptibility to cell death upon oxidative [117] and excitotoxic [118] stress, and would be particularly detrimental to the survival of neurons, as the re-establishment of Ca2+ gradients and of general ion homeostasis following neuronal signaling is highly ATP-dependent. As an aggravating factor, coordinated Ca2+ signaling is facilitated in neurons by strategic positioning of mitochondria near endoplasmic-reticulum Ca2+-release sites [20]. Therefore, reduced availability of ATP would lead to a downward spiral of an inability to remove intracellular Ca2+, Ca2+-induced mitochondrial production of reactive oxygen species, and additional depletion of mitochondrial ATP supply.
###end p 82
###begin title 83
The importance of addressing all cell types in ALS therapy
###end title 83
###begin p 84
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AQP1</italic>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CEBPD</italic>
###xml 111 119 111 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINA3</italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1 </italic>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT2 </italic>
###xml 650 653 650 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B119">119</xref>
###xml 892 895 892 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B119">119</xref>
###xml 1296 1299 1296 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B120">120</xref>
###xml 1767 1769 1767 1769 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1810 1813 1810 1813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B121">121</xref>
###xml 1814 1817 1814 1817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B122">122</xref>
During our expression analysis of the motor cortex we identified several candidate genes, such as AQP1, CEBPD, SERPINA3, and the MT1 and MT2 family members, which are exclusively expressed in non-neuronal cells. Particularly in the analysis of excitotoxicity and defense signaling, involving astrocytes and microglia, and in the interplay of inflammatory versus anti-inflammatory and of cell-death versus cell-rescue responses, the importance of different cell types involved in ALS pathology becomes apparent. The survival of motoneurons is highly dependent on their cellular environment, which is to a large majority made up of non-neuronal cells [119]. Data on the interaction of neurons with glial cells in the context of ALS are still patchy, but there is a growing understanding that non-neuronal cells have a fundamental role to play in the pathogenesis of neurodegenerative diseases [119]. Our data indicate a general increase of microglial activity and immune responses, likely aggravating ALS disease symptoms. It is known, however, that the role of microglia in neuropathies extends beyond immune responses alone. Only recently, activated microglia have been recognized to hypersensitize sensory neurons, and their role in motoneuronal excitotoxicity still remains to be investigated [120]. Moreover, our data show mixed signals from astrocytes, comprising inflammatory and anti-inflammatory responses, which have to be evaluated on an individual basis and might be modulated to slow disease progression. Astrocytes might have significant impact on the excitotoxicity and the oxidative stress responses detected by our study, as they are in close interaction with motoneurons and neuronal synapses, and themselves express all the components required for Ca2+-responsive vesicular glutamate release [121,122].
###end p 84
###begin title 85
Perspectives for ALS therapy
###end title 85
###begin p 86
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B123">123</xref>
###xml 534 537 534 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B123">123</xref>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
In the absence of effective treatments for ALS, the search for potential therapeutics continues. Like Riluzole, the only approved ALS treatment to date, the vast majority of drugs currently considered for clinical trials are based on animal models with SOD1-mutant background (85% in a recent survey [123]). Only an estimated 2% of ALS cases, however, are linked to SOD1, and resulting treatments might therefore, similar to Riluzole, have limited value as general ALS therapies. However, several candidate compounds for ALS therapy [123] address aspects of SOD1 mutants, such as oxidative stress, impaired metal binding, and defects in protein folding, that we have also identified as affected in the motor cortex of sporadic, non-SOD1-linked patients.
###end p 86
###begin p 87
###xml 545 548 545 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B124">124</xref>
###xml 549 552 549 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B125">125</xref>
###xml 793 796 793 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B126">126</xref>
###xml 923 926 920 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B127">127</xref>
###xml 1048 1051 1045 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B128">128</xref>
###xml 1262 1264 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 1308 1312 1305 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 677 685 <span type="species:ncbi:9606">patients</span>
###xml 1106 1113 <span type="species:ncbi:9606">patient</span>
A successful general therapy of ALS will have to consider the interplay and individual roles of different pathways and cell types in pathogenesis. The comprehensive analysis described here provides a full molecular portrait of the changes occurring in the motor cortex of SALS patients and provides new leads for the development of effective ALS therapies. Indeed, for the manipulation of many of the genes and pathways implicated by this study, experimental or therapeutic drugs, not yet discussed in the context of ALS, are already available [124,125]. Moreover, our findings suggest that several drugs, currently used to treat unrelated diseases, might be of benefit to ALS patients. These include bosentan, an EDN1-receptor antagonist employed against diabetes and pulmonary hypertension [126]. The widely used anti-inflammatory drug ibuprofen is an antagonist of isoleucin-1beta and of its downstream target SERPINA3 [127]. GABA antagonists such as zopiclone, used to treat insomnia, are of potential benefit to GABRA1-related excitotoxicity [128]. Significantly, symptom progression was stopped in a patient presenting with anti-PNMA2-related motoneuron degeneration by a combination of corticosteroids, intravenous immunoglobulin and antiepileptic drugs [86]. Similarly, and although it is clear from SOD1-linked FALS that all the alterations detected in ALS can have a common root and are therefore interrelated, therapy of ALS might also require combined medication to combat disease progression at multiple fronts. Many of the potential targets of this battle have been outlined by this study.
###end p 87
###begin title 88
Methods
###end title 88
###begin title 89
Characteristics of subjects
###end title 89
###begin p 90
###xml 1059 1060 1055 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 14 21 <span type="species:ncbi:9606">patient</span>
###xml 133 138 <span type="species:ncbi:9606">human</span>
###xml 412 419 <span type="species:ncbi:9606">patient</span>
###xml 743 750 <span type="species:ncbi:9606">patient</span>
###xml 805 812 <span type="species:ncbi:9606">patient</span>
###xml 1025 1032 <span type="species:ncbi:9606">patient</span>
Two groups of patient samples, consisting of eleven SALS and nine control subjects, were used in this study. Fresh-frozen samples of human motor cortex (precentral-gyrus sections) were obtained from the NICHD Brain and Tissue Bank for Developmental Disorders under contracts NO1-HD-4-3368 and NO1-HD-4-3383 and selected for post-mortem intervals (PMI) prior to freezing not exceeding 24 hours. Additionally, two patient samples were obtained as total RNA from a commercial source (Ambion, Inc.). All sample material is certified to have been obtained following international ethical guidelines and with prior consent from a fully informed donor or a member of the donor's family. All disease samples were cases of spontaneous ALS, with a mean patient age of 68.2 +/- 7.6 years. Control samples had a mean patient age of 68.7 +/- 11.0 years and were selected for matching age and for causes of death unrelated to ALS or other neurological disorders. Detailed information related to source code, age, sex, race, and storage of patient samples is given in Table 1.
###end p 90
###begin title 91
Sample preparation
###end title 91
###begin p 92
###xml 438 446 425 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-situ </italic>
Individual slices of 10 mum were produced from tissue samples at -20degreesC by a Leica CM1510S cryostat (Leica Microsystems) and stored at -80degreesC until further processing. Two slices per sample were stained by hematoxylin/eosin staining (Bio Optica) and for Nissl substance (with a microfiltered solution of cresyl violet, Sigma), respectively, to assess integrity of cellular and tissue morphology. Individual slices were used for in-situ hybridization and immunofluorescence (see below). Ten adjacent slices per sample were pooled and used for RNA extraction with Trizol (Invitrogen) following the manufacturer's standard protocol, followed by confirmation of RNA integrity by agarose gel electrophoresis.
###end p 92
###begin title 93
Microarray processing and data extraction
###end title 93
###begin p 94
###xml 424 429 <span type="species:ncbi:9606">Human</span>
Complementary RNAs (cRNAs) labeled with Cy5-CTP (Perkin-Elmer) were synthesized from 1 mug of total RNA of each sample using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies) following the manufacturer's protocol. A reference cRNA, labeled with Cy3-CTP (Perkin-Elmer), was synthesized from 1 mug of sample D2 RNA. Aliquots (750 ng) of Cy3 and Cy5 labeled cRNA targets were co-hybridized on Whole Human Genome Oligo Microarrays (Agilent Technologies). Microarray hybridization and washing were performed using reagents and instruments (hybridization chambers and rotating oven) as indicated by the manufacturer (Agilent Technologies).
###end p 94
###begin p 95
###xml 646 648 645 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1089 1092 1088 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B129">129</xref>
Microarrays were scanned at 10-mum resolution using a GenePix Personal 4100A microarray scanner and the GenePix Pro 6.0 acquisition and data-extraction software (Molecular Devices, Corp.). Raw data were processed and analyzed with Acuity 4.0 (Molecular Devices, Corp.) and GeneSpring 7.2 (Agilent Technologies). To remove unreliable data, all genes from all samples were filtered for quality to include only probe data fulfilling all of the following criteria: the spot had < 3% of saturated pixels at 635 and 532 nm; the spot was not flagged "bad", "not found" or "absent"; the spot had relatively uniform intensity and uniform background (Rgn R2 635/532 > 0.6); the spot was detectable well above background (signal-to-noise ratios at 635 or 532 nm > 3). Filtering data by quality control criteria short-listed 19,431 genes as our complete data set for Lowess normalization and subsequent analyses, out of a total of 44,233 probes (including control and alignment probes) present on the microarrays. The microarray data have been deposited in the Gene Expression Omnibus (GEO) database [129] under accession no. GSE4595.
###end p 95
###begin title 96
Pathway-based microarray analysis
###end title 96
###begin p 97
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B130">130</xref>
To analyze the gene expression changes in the context of known biological pathways we used the Gene Map Annotator and Pathway Profiler (GenMAPP) 2.0 software package [130].
###end p 97
###begin p 98
###xml 140 142 140 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 367 369 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 605 608 605 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B131">131</xref>
###xml 832 835 830 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B132">132</xref>
###xml 842 845 840 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B133">133</xref>
###xml 1159 1161 1157 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1410 1412 1408 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1453 1455 1451 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1527 1529 1525 1527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1650 1652 1648 1650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 702 707 <span type="species:ncbi:9606">child</span>
Input data for GenMAPP analysis were unique probe identifiers, corresponding UniGene cluster IDs, an average fold-change and an uncorrected P value (Welch's t-test) diseased vs. control for all 19,431 short-listed genes of our complete data set. If a UniGene cluster ID was represented by multiple probes, the probe carrying the lowest (most significant) uncorrected P value was used for pathway-based comparison with spinal-cord data [4] (see below). GenMAPP dynamically links gene-expression data to the gene ontology (GO) hierarchy of biological processes, cellular components and molecular functions [131]. For each of the GO categories in the hierarchy (nodes), and including all the genes in its child nodes, GenMAPP identifies genes that meet a user-defined criterion (>/= 1.2-fold-change in our analysis, as recommended by [132] and [133]). From the total number of genes analyzed, the number of genes in a category and the corresponding numbers of genes meeting the queried criterion a z score is calculated, which indicates the non-randomness (for high, positive z scores) of the proportion of genes meeting the criterion. Additionally, a corrected P value is calculated through permutation analysis (2000 permutations) of the data, followed by Westfall-Young adjustment for multiple hypothesis testing. Permutation analysis sets limits to the resolution of extremely significant events, so that the P value for all events with an uncorrected P < 0.0005 equals zero. Only nodes with positive z scores and a corrected P < 0.05 were considered in our analysis, with a higher z score indicating greater significance between nodes of identical P value.
###end p 98
###begin title 99
Gene-based microarray analysis
###end title 99
###begin p 100
###xml 196 198 196 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 400 402 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Of our quality-filtered data set of 19,431 genes, those with an average change greater than twofold were screened by a two-sided one-way ANOVA using Welch's t-test (with a Kolmogorov-Smirnov-test P value of 0.38 or above indicating a normal distribution of tested values), followed by the Benjamini and Hochberg False Discovery Rate procedure as a multiple testing correction. Genes with a corrected P value < 0.05 were selected as differentially expressed candidate genes. All candidate probe sequences were tested against the NCBI nucleotide database (November 2005) by BLASTN to update their annotations and confirm the specificity of each probe.
###end p 100
###begin title 101
Quantitative RT-PCR
###end title 101
###begin p 102
###xml 134 137 133 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">23 </sub>
Sample total RNA (2 mug) was reverse transcribed with the Protoscript reverse transcription kit (New England Biolabs) using the VN(dT)23 primer as recommended by the manufacturer. As a standard for relative RNA quantification (Standard cDNA), ten equivalent reactions using 2 mug pooled RNA from healthy control samples (222 ng each) were performed and the resulting cDNAs precipitated and resuspended in 50 mul water each. As a negative control for cDNA quantification, a further reaction using 2 mug of pooled RNA was performed, in which the reverse transcriptase was replaced by water. All cDNAs were tested by conventional PCR with primers for glyceraldehyde-3-phosphate dehydrogenase (New England Biolabs), using 1/50 of each cDNA (the equivalent of 40 ng total RNA).
###end p 102
###begin p 103
###xml 156 160 156 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Quantitative RT-PCR (qRT-PCR) amplifications were performed with a LightCycler (Roche Molecular Biochemicals) using the same starting amount and LightCycler(R) FastStart DNA MasterPLUS SYBR Green I reagents in a standard volume of 20 mul. Real-time detection of fluorimetric intensity of SYBR Green I, indicating the amount of PCR product formed, was measured at the end of each elongation phase. Fluorescence values measured in the log-linear phase of amplification were considered using the second-derivative-maximum method of the LightCycler Data Analysis software (Roche Molecular Biochemicals). Relative quantification was performed using serial dilutions of pooled Standard cDNA (the equivalent of 80, 40, 20, 10 and 5 ng total RNA, respectively, run in duplicate) to provide a standard curve for each run. For all experiments, the standard curve had an error of below 5% and extended over the relative quantities of all individual samples.
###end p 103
###begin p 104
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1B</italic>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1E</italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1G</italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1L</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1M</italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1X </italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT2A</italic>
Candidate genes whose differential expression was tested by gene-specific qRT-PCR analysis were parvalbumin and the metallothioneins MT1B, MT1E, MT1G, MT1L, MT1M, MT1X and MT2A. Differences in the quantity of starting material were compensated by normalization with the housekeeping genes beta-2-microglobulin (B2M) and ribosomal protein L19 (RPL19). The primers used are detailed below. Normalized fold-changes between diseased and healthy samples were calculated and tested by a two-tailed Mann-Whitney U-test (not assuming equal variances).
###end p 104
###begin title 105
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In-situ </italic>
In-situ hybridization
###end title 105
###begin p 106
###xml 522 530 522 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-situ </italic>
###xml 593 596 593 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B134">134</xref>
###xml 63 68 <span type="species:ncbi:9606">human</span>
cDNAs corresponding to four mRNAs were synthesized by PCR from human brain RNA using specific forward and reverse primers. PCR fragments were subcloned into pCR4Blunt-TOPO vector (Invitrogen) and the orientation of the insert was determined by sequencing. Following linearization of plasmids by restriction endonucleases, riboprobes containing Cy3-CTP (sense) or Cy5-CTP (antisense) (Perkin-Elmer) were synthesized by T3 and T7 polymerase, respectively, using the MAXIscript In Vitro Transcription Kit (Ambion, Inc.). The in-situ hybridization procedure was performed as previously described [134]. Fluorescent hybridization signals were obtained by scanning sections at 5-mum resolution using a GenePix Personal 4100A scanner (Molecular Devices, Corp.). No signal was detected in control brain sections hybridized with the sense riboprobes or pretreated with RNase before hybridization with the antisense probes. Evaluation of hybridization signals were obtained by using a computer-assisted image analysis system and the Photoshop 7.0 software (Adobe Systems, Inc.).
###end p 106
###begin title 107
Immunoblots
###end title 107
###begin p 108
###xml 181 182 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 191 192 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 194 195 194 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 540 546 <span type="species:ncbi:9986">rabbit</span>
###xml 617 621 <span type="species:ncbi:9925">goat</span>
###xml 780 786 <span type="species:ncbi:9986">rabbit</span>
###xml 848 852 <span type="species:ncbi:9925">goat</span>
Protein was extracted from human motor-cortex samples using standard methods. Following SDS-PAGE separation on 10-12% gels and semi-dry protein blotting (transfer buffer 10 mM NaHCO3, 3 mM Na2CO3, 20% methanol, pH 9.9) to nitrocellulose Hybond membranes (Amersham Pharmacia Biotech), blots were blocked (0.1% Tween, 3% milk PBS), incubated with the appropriate primary antibody at 4degreesC over-night, and following three washes with PBS were incubated with secondary antibody. Primary antibodies (all Santa Cruz Biotechnology, Inc.) were rabbit antibodies ANXA2 (SC-9061), AQP1 (SC-20810), and CANX (SC-11397), and goat antibody NRGN (SC-18336), all at 1:100 dilution. As HRP-conjugated secondary antibodies (all Amersham Pharmacia Biotech) we applied a 1:4000 dilution of anti-rabbit antibody for detection of ANXA2, AQP1, and CANX, and of anti-goat antibody for NRGN. Immunoblots were visualized using the Enhanced Chemiluminescence System (Amersham Pharmacia Biotech). Band intensities were determined as background-corrected volume measurements using the ImageQuant TL software (Amersham Pharmacia Biotech), were equalized using CANX as a loading reference (which has not been linked to ALS and in our microarray analysis showed an mRNA ratio diseased vs. control of 0.97), and were subjected to statistical analysis using a two-tailed, heteroscedastic Student's t-test in Excel (Microsoft Corp.).
###end p 108
###begin title 109
Primers
###end title 109
###begin p 110
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PVALB </italic>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1B </italic>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1E </italic>
###xml 556 561 556 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1G </italic>
###xml 658 663 658 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1L </italic>
###xml 759 764 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1M </italic>
###xml 863 868 863 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT1X </italic>
###xml 964 969 964 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MT2A </italic>
###xml 1066 1072 1066 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPL19 </italic>
###xml 1167 1171 1167 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
The following forward (FP) and reverse (RP) primers were used for qRT-PCR analysis: PVALB (GenBank Accession No: , forward primer (FP): 5'-acgctgaggacatcaagaagg-3', 5'-caattttgccgtccccatc-3), reverse primer (RP): MT1B (GenBank Accession No.: , FP1: 5'-actccaggcttgtcttggctcc-3', RP1: 5'-tgggagcagggctctcccaa-3', FP2: 5'-ttgcctaggaactccaggcttgt-3', RP2: 5'-gcagcggcacttctctgatgag-3', FP3: 5'-tgctgctcttgctgccccgt-3', RP3: 5'-aaagaatgtagcaaaccggtcaggg-3'), MT1E (GenBank Accession No.: , FP: 5'-ccttcttccccaggctgctgt-3', RP: 5'-aatgcagcaaatggctcagtgttg-3'), MT1G (GenBank Accession No.: , FP: 5'-gcatctgcaaaggggcatcg-3', RP: 5'-aaaggaatgtagcaaaggggtcaaga-3'), MT1L (GenBank Accession No.: , FP: 5'-gggctcctgctcctgtgcca-3', RP: 5'-ggaatgtagcaaatgctcagggttg-3'), MT1M (GenBank Accession No.: , FP: 5'-tggtgtctcctgcgcctgca-3', RP: 5'-aatgcagcaaatggctcagtatcgtatt-3'), MT1X (GenBank Accession No.: , FP: 5'-tgctgctcctgctgccctgt-3', RP: 5'-aaaagatgtagcaaacgggtcaggg-3'), MT2A (GenBank Accession No.: , FP: 5'-cgactctagccgcctcttca-3', RP: 5'-gaaaaaggaatatagcaaacggtcac-3'), RPL19 (GenBank Accession No.: , FP: 5'-ggctgctcagaagataccgtg-3', RP: 5'-ggcgcttgcgtgcttccttg-3') and B2M (GenBank Accession No.: , FP: 5'-agcgtactccaaagattcaggtt-3', RP: 5'-tacatgtctcgatcccacttaactat-3'). Specificity of PCR products obtained was characterized by melting-curve analysis followed by gel electrophoresis and DNA sequencing.
###end p 110
###begin p 111
###xml 57 65 57 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-situ </italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATP1A3 </italic>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NRGN </italic>
###xml 272 278 272 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PVALB </italic>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANXA2 </italic>
The following primers were used to amplify fragments for in-situ hybridization: ATP1A3 (GenBank Accession No.: ; FP: 5'-tcaagaaggaggtggctatg-3', RP: 5'-gagaagcagccagtgatgat-3');NRGN (GenBank Accession No.: ; FP: 5'-gactaggccagaactgagca-3', RP: 5'-agtggcacggagatgtagg-3'); PVALB (GenBank Accession No.: ; FP: 5'-agttgcaggatgtcgatgac-3', RP: 5'-ccagagtggagaattcgtca-3'); ANXA2 (GenBank Accession No.: ; FP: 5'-gatcatctgctccagaacca-3', RP: 5'-gagtcatacagccgatcagc-3').
###end p 111
###begin title 112
Comparison with SALS spinal-cord and AD hippocampus expression data
###end title 112
###begin p 113
###xml 42 43 42 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 741 743 732 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
For SALS spinal-cord data, series GSE833 [4] of GEO was imported into Excel (Microsoft Corp.), and all UniGene ID numbers were updated (January 2006) using probe identities of the HuGeneFL array (Affymetrix, Inc.) in the NetAffxtrade mark Analysis Center (Affymetrix, Inc.). Fold-changes were calculated for five SALS samples (GSM6827, GSM6828, GSM6834, GSM6835, GSM6836) vs. four control samples (GSM6826, GSM6829, GSM6830, GSM6831), for genes with a corresponding UniGene ID and showing a signal level of > 100 in at least five of these nine samples (3276 genes of a total of 7070 present on the HuGeneFL array). For 2266 of these genes the equivalent, quality-filtered (see above) non-redundant Agilent probes with the lowest uncorrected P value (see GenMAPP analysis above) were short-listed to calculate a correlation coefficient r for the expression ratios in spinal cord and motor cortex using Excel. A correlation coefficient was determined for all 2266 shared genes and for 23 shared genes corresponding to candidate genes identified in motor cortex by gene-based analysis, respectively.
###end p 113
###begin p 114
For AD hippocampus data, an analogous procedure was followed, using seven severe-AD samples (GSM21203, GSM21206, GSM21207, GSM21208, GSM21212, GSM21213, GSM21229) vs. nine controls (GSM21215, GSM21217, GSM21218, GSM21219, GSM21220, GSM21221, GSM21226, GSM21231, GSM21232) of the GEO series GSE1297, and including genes showing a signal level of > 100 in at least eight of these 16 samples, resulting in a shared dataset of 6375 reliably detectable genes. A correlation coefficient was determined for the expression ratios diseased vs. control for these shared genes and for 38 shared genes identified as differentially expressed in our SALS study, respectively.
###end p 114
###begin title 115
Immunofluorescence
###end title 115
###begin p 116
###xml 189 193 <span type="species:ncbi:9913">calf</span>
###xml 204 210 <span type="species:ncbi:9913">bovine</span>
###xml 822 827 <span type="species:ncbi:10090">mouse</span>
###xml 887 893 <span type="species:ncbi:9986">rabbit</span>
Tissue slices were submerged for 10 minutes in acetone at -20degreesC, followed by washes in phosphate-buffered saline (PBS), and incubation with 0.5% Triton in blocking solution (2% fetal calf serum, 2% bovine serum albumin, 0.2% fish-skin gelatine) for 10 minutes. Tissue slices were then incubated with 10-mM copper (II) sulfate and 50-mM ammonium acetate (pH 5.0) for 30 min to quench autofluorescence, followed by washes with PBS. Primary antibodies were co-incubated over-night at 4degreesC at dilutions of 1:50 for AQP1 (AQP1 antibody H-55, Santa Cruz Biotechnology, Inc.) and 1:3000 for neurofilaments (200 kDa + 160 kDa (phospho) antibody SMI 31, Abcam) in blocking solution without Triton X-100, followed by washes in PBS and co-incubation of secondary antibodies at room temperature at dilutions of 1:1500 anti-mouse Alexa Fluor 568 (A-11034, Molecular Probes) and 1:500 anti-rabbit Alexa Fluor 488 (A-21124, Molecular Probes). Tissue sections were then washed in PBS, incubated with Hoechst33342 as a DNA counter stain, washed in PBS, briefly air-dried, and mounted for microscopy in 10% Mowiol, 1% 1,4-Diazabicyclo [2.2.2]octane, and 25% glycerol in 0.1-M Tris buffer (pH 8). Images were acquired using an Axiovert 200 M microscope with the AxioVision 4.5 image acquisition software, the Apotome module and the transparency projection option for Z stacks of the Inside4D visualization module (all Carl Zeiss Inc.).
###end p 116
###begin title 117
Abbreviations
###end title 117
###begin p 118
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 130 133 130 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B135">135</xref>
For Unigene cluster IDs of candidate genes see Figure 3, conforming to the HUGO Gene Nomenclature Committee (HGNC) database (see [135]). All abbreviations are defined at their first appearance in the text, and in the legends of tables and figures, as follows:
###end p 118
###begin p 119
AD - Alzheimer's disease
###end p 119
###begin p 120
ALS - amyotrophic lateral sclerosis
###end p 120
###begin p 121
BP - biological process
###end p 121
###begin p 122
CC - cellular component
###end p 122
###begin p 123
EGL - external granular layer
###end p 123
###begin p 124
EPL - external pyramidal layer
###end p 124
###begin p 125
FALS - familial ALS
###end p 125
###begin p 126
FP - forward primer
###end p 126
###begin p 127
GO - gene ontology
###end p 127
###begin p 128
IGL - internal granular layer
###end p 128
###begin p 129
IPL - internal pyramidal layer
###end p 129
###begin p 130
LMN - lower motoneuron
###end p 130
###begin p 131
NF - neurofilament
###end p 131
###begin p 132
MF - molecular function
###end p 132
###begin p 133
MFL - multiform layer
###end p 133
###begin p 134
ML - molecular layer
###end p 134
###begin p 135
RP - reverse primer
###end p 135
###begin p 136
qRT-PCR - quantitative reverse-transcriptase PCR
###end p 136
###begin p 137
SALS - sporadic ALS
###end p 137
###begin p 138
TCA - tricarboxylic acid cycle
###end p 138
###begin p 139
UMN - upper motoneuron
###end p 139
###begin title 140
Authors' contributions
###end title 140
###begin p 141
CWL participated in the design of the study, carried out microarray experiments, their pathway-based statistical analysis and comparisons with publicly available microarray data, participated in gene-based statistical analyses, performed qRT-PCR analyses, immunofluorescence experiments and statistical analysis of immunoblot data, and drafted the manuscript. AT performed in-situ hybridization experiments. MP performed immunoblots. NS conceived of the study, participated in its design and coordination, and helped to draft the manuscript. SC designed the study, participated in its coordination, performed gene-based statistical analysis of microarray data, statistical analysis of in-situ hybridization data, and made major contributions to the manuscript. All authors have read and approved the final manuscript.
###end p 141
###begin title 142
Acknowledgements
###end title 142
###begin p 143
We thank Alfia Corsino, Maria Patrizia D'Angelo and Francesco Marino for administrative and technical support, and Kleopas Kleopa for discussions. This research was supported by grants from the Ministry of Health and the Ministry of Education, University and Research (Italy) (S.C.), and from the A.G. Leventis Foundation (France) and Telethon Foundation (Cyprus) (N.S.).
###end p 143
###begin article-title 144
Molecular and cellular pathways of neurodegeneration in motor neurone disease
###end article-title 144
###begin article-title 145
Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays
###end article-title 145
###begin article-title 146
Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis
###end article-title 146
###begin article-title 147
###xml 34 39 <span type="species:ncbi:9606">human</span>
Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter
###end article-title 147
###begin article-title 148
The management of motor neurone disease
###end article-title 148
###begin article-title 149
Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS
###end article-title 149
###begin article-title 150
Sporadic lower motor neuron disease with adult onset: classification of subtypes
###end article-title 150
###begin article-title 151
Diffusion tensor imaging in amyotrophic lateral sclerosis: volumetric analysis of the corticospinal tract
###end article-title 151
###begin article-title 152
Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS)
###end article-title 152
###begin article-title 153
Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis
###end article-title 153
###begin article-title 154
The corticospinal system: from development to motor control
###end article-title 154
###begin article-title 155
Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS
###end article-title 155
###begin article-title 156
Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET
###end article-title 156
###begin article-title 157
Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene
###end article-title 157
###begin article-title 158
Integrated genomic and proteomic analyses of gene expression in Mammalian cells
###end article-title 158
###begin article-title 159
Aquaporins in brain: distribution, physiology, and pathophysiology
###end article-title 159
###begin article-title 160
###xml 64 69 <span type="species:ncbi:9606">human</span>
Localization of aquaporin-1 water channel in glial cells of the human peripheral nervous system
###end article-title 160
###begin article-title 161
Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses
###end article-title 161
###begin article-title 162
Perspective: emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion
###end article-title 162
###begin article-title 163
Calcium, ATP, and ROS: a mitochondrial love-hate triangle
###end article-title 163
###begin article-title 164
Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis
###end article-title 164
###begin article-title 165
Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis
###end article-title 165
###begin article-title 166
Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress
###end article-title 166
###begin article-title 167
###xml 135 139 <span type="species:ncbi:10090">mice</span>
Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice
###end article-title 167
###begin article-title 168
The chromogranin-secretogranin family
###end article-title 168
###begin article-title 169
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Distribution of GABAA receptor mRNA in the motor cortex of ALS patients
###end article-title 169
###begin article-title 170
Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism
###end article-title 170
###begin article-title 171
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
Global loss of Na,K-ATPase and its nitric oxide-mediated regulation in a transgenic mouse model of amyotrophic lateral sclerosis
###end article-title 171
###begin article-title 172
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease
###end article-title 172
###begin article-title 173
###xml 20 30 <span type="species:ncbi:7227">Drosophila</span>
A novel leg-shaking Drosophila mutant defective in a voltage-gated K(+)current and hypersensitive to reactive oxygen species
###end article-title 173
###begin article-title 174
Reduction of KCC2 expression and GABAA receptor-mediated excitation after in vivo axonal injury
###end article-title 174
###begin article-title 175
Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early synaptic inhibition
###end article-title 175
###begin article-title 176
Parvalbumin is a marker of ALS-resistant motor neurons
###end article-title 176
###begin article-title 177
Calcium binding proteins in motoneurons at low and high risk for degeneration in ALS
###end article-title 177
###begin article-title 178
Calcium: the Darth Vader of ALS
###end article-title 178
###begin article-title 179
###xml 6 11 <span type="species:ncbi:9606">human</span>
Novel human ZAKI-4 isoforms: hormonal and tissue-specific regulation and function as calcineurin inhibitors
###end article-title 179
###begin article-title 180
High level calcineurin activity predisposes neuronal cells to apoptosis
###end article-title 180
###begin article-title 181
Small proteins that modulate calmodulin-dependent signal transduction: effects of PEP-19, neuromodulin, and neurogranin on enzyme activation and cellular homeostasis
###end article-title 181
###begin article-title 182
A new role for IQ motif proteins in regulating calmodulin function
###end article-title 182
###begin article-title 183
Urea transporter expression in aging kidney and brain during dehydration
###end article-title 183
###begin article-title 184
The SLC14 gene family of urea transporters
###end article-title 184
###begin article-title 185
Involvement of water channels in synaptic vesicle swelling
###end article-title 185
###begin article-title 186
Proteasome inhibition induces selective motor neuron death in organotypic slice cultures
###end article-title 186
###begin article-title 187
Mechanisms of neurodegenerative disorders: Part 1: protein aggregates
###end article-title 187
###begin article-title 188
Genes, proteins, and neurotoxins involved in Parkinson's disease
###end article-title 188
###begin article-title 189
The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility
###end article-title 189
###begin article-title 190
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice
###end article-title 190
###begin article-title 191
Serpin=serine protease-like complexes within neurofilament conglomerates of motoneurons in amyotrophic lateral sclerosis
###end article-title 191
###begin article-title 192
Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA
###end article-title 192
###begin article-title 193
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation
###end article-title 193
###begin article-title 194
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Chymotrypsin-like proteases contribute to human monocytic THP-1 cell as well as human microglial neurotoxicity
###end article-title 194
###begin article-title 195
Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta
###end article-title 195
###begin article-title 196
A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10)
###end article-title 196
###begin article-title 197
###xml 95 105 <span type="species:ncbi:7227">Drosophila</span>
Kinesin mutations cause motor neuron disease phenotypes by disrupting fast axonal transport in Drosophila
###end article-title 197
###begin article-title 198
Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration
###end article-title 198
###begin article-title 199
Mutations in neurofilament genes are not a significant primary cause of non-SOD1-mediated amyotrophic lateral sclerosis
###end article-title 199
###begin article-title 200
Pathogenesis of two axonopathies does not require axonal neurofilaments
###end article-title 200
###begin article-title 201
Amyotrophic lateral sclerosis
###end article-title 201
###begin article-title 202
Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant
###end article-title 202
###begin article-title 203
Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects?
###end article-title 203
###begin article-title 204
AF1q, a differentially expressed gene during neuronal differentiation, transforms HEK cells into neuron-like cells
###end article-title 204
###begin article-title 205
Four structurally distinct neuron-specific olfactomedin-related glycoproteins produced by differential promoter utilization and alternative mRNA splicing from a single gene
###end article-title 205
###begin article-title 206
Differentially expressed olfactomedin-related glycoproteins (Pancortins) in the brain
###end article-title 206
###begin article-title 207
Noelin-1 is a secreted glycoprotein involved in generation of the neural crest
###end article-title 207
###begin article-title 208
###xml 60 67 <span type="species:ncbi:8355">Xenopus</span>
The secreted glycoprotein Noelin-1 promotes neurogenesis in Xenopus
###end article-title 208
###begin article-title 209
NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in neuronal differentiation
###end article-title 209
###begin article-title 210
Neuronal Ca2+ sensor protein VILIP-1 affects cGMP signalling of guanylyl cyclase B by regulating clathrin-dependent receptor recycling in hippocampal neurons
###end article-title 210
###begin article-title 211
Cyclase-associated protein 1 (CAP1) promotes cofilin-induced actin dynamics in mammalian nonmuscle cells
###end article-title 211
###begin article-title 212
Actin has a molecular scaffolding, not propulsive, role in presynaptic function
###end article-title 212
###begin article-title 213
Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle
###end article-title 213
###begin article-title 214
Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein
###end article-title 214
###begin article-title 215
GP55 inhibits both cell adhesion and growth of neurons, but not non-neuronal cells, via a G-protein-coupled receptor
###end article-title 215
###begin article-title 216
The diacylglycerol-binding protein {alpha}1-chimaerin regulates dendritic morphology
###end article-title 216
###begin article-title 217
Neurotransmitter release: the dark side of the vacuolar-H+ATPase
###end article-title 217
###begin article-title 218
Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ
###end article-title 218
###begin article-title 219
A Second SNARE Role for Exocytic SNAP25 in Endosome Fusion
###end article-title 219
###begin article-title 220
Characterization of KIAA1427 protein as an atypical synaptotagmin (Syt XIII)
###end article-title 220
###begin article-title 221
Unraveling the mechanism of the vesicle transport ATPase NSF, the N-ethylmaleimide-sensitive factor
###end article-title 221
###begin article-title 222
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis
###end article-title 222
###begin article-title 223
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Internalization of IgG in motoneurons of patients with ALS: selective or nonselective?
###end article-title 223
###begin article-title 224
Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport
###end article-title 224
###begin article-title 225
IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis
###end article-title 225
###begin article-title 226
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line
###end article-title 226
###begin article-title 227
###xml 113 121 <span type="species:ncbi:9606">patients</span>
In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients
###end article-title 227
###begin article-title 228
Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals
###end article-title 228
###begin article-title 229
Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy
###end article-title 229
###begin article-title 230
###xml 75 83 <span type="species:ncbi:9606">patients</span>
A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer
###end article-title 230
###begin article-title 231
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human IgGFc binding protein (FcgammaBP) in colonic epithelial cells exhibits mucin-like structure
###end article-title 231
###begin article-title 232
###xml 48 53 <span type="species:ncbi:9606">human</span>
Detection of Fcgamma binding protein antigen in human sera and its relation with autoimmune diseases
###end article-title 232
###begin article-title 233
CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease
###end article-title 233
###begin article-title 234
Role of 14-3-3 eta as a positive regulator of the glucocorticoid receptor transcriptional activation
###end article-title 234
###begin article-title 235
Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II
###end article-title 235
###begin article-title 236
Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules
###end article-title 236
###begin article-title 237
Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo
###end article-title 237
###begin article-title 238
Tissue plasminogen activator as a modulator of neuronal survival and function
###end article-title 238
###begin article-title 239
###xml 77 82 <span type="species:ncbi:9606">human</span>
Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells
###end article-title 239
###begin article-title 240
SB209670, a potent endothelin receptor antagonist, prevents or delays axonal degeneration after spinal cord injury
###end article-title 240
###begin article-title 241
Endothelin-1 overexpression leads to further water accumulation and brain edema after middle cerebral artery occlusion via aquaporin 4 expression in astrocytic end-feet
###end article-title 241
###begin article-title 242
Endothelins negatively regulate glial glutamate transporter expression
###end article-title 242
###begin article-title 243
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Increased sensitivity to acute and persistent pain in neuron-specific endothelin-1 knockout mice
###end article-title 243
###begin article-title 244
Endothelin-1 protects astrocytes from hypoxic/ischemic injury
###end article-title 244
###begin article-title 245
Endothelin-1 and angiogenesis in cancer
###end article-title 245
###begin article-title 246
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets
###end article-title 246
###begin article-title 247
Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth
###end article-title 247
###begin article-title 248
Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation
###end article-title 248
###begin article-title 249
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis
###end article-title 249
###begin article-title 250
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
###end article-title 250
###begin article-title 251
Metallothioneins are multipurpose neuroprotectants during brain pathology
###end article-title 251
###begin article-title 252
Overexpression of metallothionein protects cultured motor neurons against oxidative stress, but not mutant Cu/Zn-superoxide dismutase toxicity
###end article-title 252
###begin article-title 253
The role in neural patterning of translation initiation factor eIF4AII; induction of neural fold genes
###end article-title 253
###begin article-title 254
EIF4A2 Is a Positional Candidate Gene at the 3q27 Locus Linked to Type 2 Diabetes in French Families
###end article-title 254
###begin article-title 255
###xml 114 119 <span type="species:ncbi:10090">mouse</span>
Expression patterns of the novel imprinted genes Nap1l5 and Peg13 and their non-imprinted host genes in the adult mouse brain
###end article-title 255
###begin article-title 256
Histone chaperones, a supporting role in the limelight
###end article-title 256
###begin article-title 257
Minireview: GNAS: normal and abnormal functions
###end article-title 257
###begin article-title 258
Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis
###end article-title 258
###begin article-title 259
Impact of hypoglycemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage
###end article-title 259
###begin article-title 260
Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis
###end article-title 260
###begin article-title 261
Transient inhibition of glutamate uptake in vivo induces neurodegeneration when energy metabolism is impaired
###end article-title 261
###begin article-title 262
Neuroscience. The dark side of glia
###end article-title 262
###begin article-title 263
Immune and inflammatory mechanisms in neuropathic pain
###end article-title 263
###begin article-title 264
Vesicular glutamate transporter-dependent glutamate release from astrocytes
###end article-title 264
###begin article-title 265
Astrocytes coordinate synaptic networks: balanced excitation and inhibition
###end article-title 265
###begin article-title 266
Neuroprotective agents for clinical trials in ALS: a systematic assessment
###end article-title 266
###begin article-title 267
TTD: Therapeutic Target Database
###end article-title 267
###begin article-title 268
DrugBank: a comprehensive resource for in silico drug discovery and exploration
###end article-title 268
###begin article-title 269
Bosentan
###end article-title 269
###begin article-title 270
Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models
###end article-title 270
###begin article-title 271
Indiplon is a high-affinity positive allosteric modulator with selectivity for {alpha}1 subunit containing GABAA receptors
###end article-title 271
###begin article-title 272
NCBI GEO: mining millions of expression profiles--database and tools
###end article-title 272
###begin article-title 273
MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data
###end article-title 273
###begin article-title 274
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium
###end article-title 274
###begin article-title 275
Identifying genetic networks underlying myometrial transition to labor
###end article-title 275
###begin article-title 276
###xml 48 53 <span type="species:ncbi:9606">human</span>
Time- and exercise-dependent gene regulation in human skeletal muscle
###end article-title 276
###begin article-title 277
###xml 88 91 <span type="species:ncbi:10116">rat</span>
Spatial learning induced changes in expression of the ryanodine type II receptor in the rat hippocampus
###end article-title 277
###begin article-title 278
The HUGO Gene Nomenclature Database, 2006 updates
###end article-title 278

